Home Featured Page 159

Featured

Latest

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

PT314 – Daniel McQueen, MA – Vital Psychedelic Conversations

Hallucinating Long After the Trip is Over: HPPD – Part 1

Psychedelics Today Has Hit 3 Million Downloads!

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

Psychedelic Research Bulletin: March 2022

MYND Life Sciences Announces $3.5 Million Share Offering

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

COMPASS Pathways partners with One Mind to fund Rising Star Awards...

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

1...158159160...291 Page 159 of 291

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

PT314 – Daniel McQueen, MA – Vital Psychedelic Conversations

Hallucinating Long After the Trip is Over: HPPD – Part 1

Psychedelics Today Has Hit 3 Million Downloads!

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

Psychedelic Research Bulletin: March 2022

MYND Life Sciences Announces $3.5 Million Share Offering

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

COMPASS Pathways partners with One Mind to fund Rising Star Awards...

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

EDITOR PICKS

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY